Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether mammalian target of rapamycin complex 1 (mTORC1) inhibitors could reduce seizure frequency in children with tuberous sclerosis complex (TSC). METHODS: Due to slow inclusion rate, target inclusion of 30 children was not reached. Twenty-three children with TSC and intractable epilepsy (age 1.8-10.9 years) were randomly assigned (1:1) to open-label, add-on sirolimus treatment immediately or after 6 months. Sirolimus was titrated to trough levels of 5-10 ng/mL. Primary endpoint was seizure frequency change during the sixth month of sirolimus treatment. RESULTS: Intention-to-treat analysis showed sirolimus treatment resulted in 41% seizure frequency decrease (95% confidence interval [CI] -69% to +14%; p = 0.11) compared to the standard-care period. Per protocol analysis of 14 children who reached sirolimus target trough levels in the sixth sirolimus month showed a seizure frequency decrease of 61% (95% CI -86% to +6%; p = 0.06). Cognitive development did not change. All children had adverse events. Five children discontinued sirolimus prematurely. CONCLUSIONS: We describe a randomized controlled trial for a non-antiepileptic drug that directly targets a presumed causal mechanism of epileptogenesis in a genetic disorder. Although seizure frequency decreased, especially in children reaching target trough levels, we could not show a significant benefit. Larger trials or meta-analyses are needed to investigate if patients with TSC with seizures benefit from mTORC1 inhibition. This trial was registered at trialregister.nl (NTR3178) and supported by the Dutch Epilepsy Foundation. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that sirolimus does not significantly reduce seizure frequency in children with TSC and intractable epilepsy. The study lacked the precision to exclude a benefit from sirolimus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Northrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.001 · Cited by 1,502
Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882
Neurological and neuropsychiatric aspects of tuberous sclerosis complex
Curatolo, P., Moavero, R., & de Vries, P. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00069-1 · Cited by 600 · cited 1×
“Cognitive development is negatively affected by epilepsy.(5,6) TSC is caused by mutations in TSC1 or TSC2,(7,8) resulting in upregulated activity of mammalian target of rapamycin complex 1 (mTORC1).”
Background
Cited by
Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations
Curatolo, P., Nabbout, R., Lagae, L., Aronica, E., Ferreira, J. C., Feucht, M., Hertzberg, C., Jansen, A. C., Jansen, F., Kotulska, K., et al. (2018) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2018.05.006 · Cited by 190
Self-citationmTOR and neuroinflammation in epilepsy: implications for disease progression and treatment
Ravizza, T., Scheper, M., Di Sapia, R., Gorter, J., Aronica, E., & Vezzani, A. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-024-00805-1 · Cited by 141
“However, the study did not show improvement in neurodevelopment or behaviour, potentially owing to factors such as a small sample size and selected outcomes 54 .”
Li, M., Zhou, Y., Chen, C., Yang, T., Zhou, S., Chen, S., Wu, Y., & Cui, Y. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1012-x · Cited by 83
Reijnders, M. R. F., Kousi, M., van Woerden, G. M., Klein, M., Bralten, J., Mancini, G. M. S., van Essen, T., Proietti-Onori, M., Smeets, E. E. J., van Gastel, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00933-6 · Cited by 76
Zimmer, T. S., Broekaart, D. W. M., Gruber, V.-E., van Vliet, E. A., Mühlebner, A., & Aronica, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01028 · Cited by 48
“Importantly, mTOR hyperactivity seems to be directly linked to epileptogenesis as mTOR inhibitors can suppress seizures in preclinical TSC models (28, 29), as well as in clinical studies aimed at treating TSC and SEGAs (16–19, 30, 31).”
Metadata
- Authors
- Overwater, I. E., Rietman, A. B., Bindels-de Heus, K., Looman, C. W. N., Rizopoulos, D., Sibindi, T. M., Cherian, P. J., Jansen, F. E., Moll, H. A., Elgersma, Y., & de Wit, M.-C. Y.
- Venue
- Neurology
- Published
- 2016-09-06
- Volume
- 87
- Issue
- 10
- Pages
- 1011-1018
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2515754624
- Cited by
- 89
- References
- 4
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial. https://app.cochat.ai/papers/10.1212/wnl.0000000000003077
- The paper
- Overwater, I. E., Rietman, A. B., Bindels-de Heus, K., Looman, C. W. N., Rizopoulos, D., Sibindi, T. M., Cherian, P. J., Jansen, F. E., Moll, H. A., Elgersma, Y., & de Wit, M.-C. Y. (2016). Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial. Neurology. https://doi.org/10.1212/wnl.0000000000003077
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.